Cargando…

Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers

BACKGROUND: Tumor mutational burden (TMB) may be a predictive biomarker of immune checkpoint inhibitor (ICI) responsiveness. Genomic landscape heterogeneity is a well-established cancer feature. Molecular characteristics may differ even within the same tumor specimen and undoubtedly evolve with time...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pham, Timothy V., Goodman, Aaron M., Sivakumar, Smruthy, Frampton, Garrett, Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513181/ https://www.ncbi.nlm.nih.gov/pubmed/34641956 http://dx.doi.org/10.1186/s13073-021-00979-8

Ejemplares similares

Tumor mutational burden is not predictive of cytotoxic chemotherapy response
por: Nikanjam, Mina, et al.
Publicado: (2020)

Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
por: Pham, Timothy V., et al.
Publicado: (2020)

MHC-I genotype and tumor mutational burden predict response to immunotherapy
por: Goodman, Aaron M., et al.
Publicado: (2020)

Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers
por: Vu, Peter, et al.
Publicado: (2020)

Relationship between tumor mutational burden and maximum standardized uptake value in 2-[(18)F]FDG PET (positron emission tomography) scan in cancer patients
por: Haghighat Jahromi, Amin, et al.
Publicado: (2020)

APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy
por: Boichard, Amélie, et al.
Publicado: (2018)

Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
por: Bieg‐Bourne, Cheyennedra C., et al.
Publicado: (2020)

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies
por: Goodman, Aaron M., et al.
Publicado: (2017)

Schnitzler syndrome associated with MYD88 L265P mutation
por: Goodman, Aaron M., et al.
Publicado: (2019)

High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting
por: Joshi, Rushikesh S., et al.
Publicado: (2022)

Liquid biopsy: current technology and clinical applications
por: Nikanjam, Mina, et al.
Publicado: (2022)

Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
por: Ikeda, Sadakatsu, et al.
Publicado: (2016)

Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer
por: Sivakumar, Smruthy, et al.
Publicado: (2022)

Real‐World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim‐Chester Disease
por: Saunders, Ila M., et al.
Publicado: (2019)

Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues
por: Li, Alex M., et al.
Publicado: (2019)

Autoimmune HLA Alleles and Neoepitope Presentation Predict Post-Allogenic Transplant Relapse
por: Castro, Andrea, et al.
Publicado: (2023)

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patients
por: Nikanjam, Mina, et al.
Publicado: (2019)

Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications
por: Cohen, Philip R., et al.
Publicado: (2015)

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy
por: Magbanua, Mark Jesus M., et al.
Publicado: (2022)

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
por: Cohen, Philip R., et al.
Publicado: (2017)

Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy
por: Cohen, Philip R, et al.
Publicado: (2020)

Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations
por: Sivakumar, Smruthy, et al.
Publicado: (2023)

High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations
por: Boichard, Amélie, et al.
Publicado: (2017)

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes
por: Kurzrock, Razelle, et al.
Publicado: (2015)

Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible
por: Jensen, Taylor J., et al.
Publicado: (2021)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
por: El-Osta, Hazem, et al.
Publicado: (2011)

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers
por: Liu, Sariah, et al.
Publicado: (2016)

Case Report: Early detection of pancreatic pre-cancer lesion in multimodal approach with exosome liquid biopsy
por: Dhani, Harmeet, et al.
Publicado: (2023)

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay
por: Schwaederle, Maria, et al.
Publicado: (2016)

Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015)

The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match
por: Subbiah, Vivek, et al.
Publicado: (2018)

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
por: Agashe, Ruchi, et al.
Publicado: (2020)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
por: Janku, Filip, et al.
Publicado: (2011)

Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center
por: Sharabi, Andrew, et al.
Publicado: (2017)

Molecular landscape of pancreatic cancer: implications for current clinical trials
por: Heestand, Gregory M., et al.
Publicado: (2015)

Click chemistry, 3D-printing, and omics: the future of drug development
por: Kurzrock, Razelle, et al.
Publicado: (2015)

Fool’s gold, lost treasures, and the randomized clinical trial
por: Stewart, David J, et al.
Publicado: (2013)

Cutaneous Metastatic Cancer: Carcinoma Hemorrhagiectoides Presenting as the Shield Sign
por: Cohen, Philip R, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6to0968uosdgog6dvpn95r5jp1